Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Olaparib in Clinical Practice Among Chinese Patients.

NCT04560452 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04560452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Olaparib in Clinical Practice Among Chinese Patients.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 15, 2021
Completion date
September 5, 2025
Enrollment
1,018 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, prostate cancer